Ligand Pharmaceuticals LGND Development and Licensing of Biopharmaceutical Assets — Interest Expense, Nonoperating

Similar metrics at other companies

PTCTLife Science — Interest Expense Nonoperating

$67.02M+30.5%

CVCOFinancial services — Interest Expense, Nonoperating

$0—

ONDSInterest Expense, Nonoperating

$338K-91.3%

MSGSSingle Operating Segment — Interest Expense, Nonoperating

$4.84M-3.7%

MSMReportable Segment — Interest Expense, Nonoperating

$5.59M-10.3%

CENXReportable Segment — Interest Expense, Nonoperating

$9.9M-1.0%

Questions, answered.

What is Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — interest expense, nonoperating?

Ligand Pharmaceuticals (LGND) reported development and licensing of biopharmaceutical assets — interest expense, nonoperating of $1.75M in Q1 2026.

How has Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — interest expense, nonoperating changed year-over-year?

Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — interest expense, nonoperating increased by 101.5% year-over-year, from $867K to $1.75M.

What is the long-term trend for Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — interest expense, nonoperating?

Over 3 years (2022 to 2025), Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — interest expense, nonoperating has grown at a 37.9% compound annual growth rate (CAGR), from $1.8M to $4.72M.

What does development and licensing of biopharmaceutical assets — interest expense, nonoperating mean?

This metric represents the costs incurred on debt obligations and other financing arrangements that are classified as non-operating expenses for the segment. It measures the financial burden of the segment's capital structure and leverage. Investors monitor this to assess the impact of debt servicing on the segment's net profitability.